Biome Australia Ltd
ASX:BIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biome Australia Ltd
ASX:BIO
|
AU |
|
Z
|
Zendesk Inc
F:0ZD
|
US |
|
A
|
Anhui Hyea Aromas Co Ltd
SZSE:300886
|
CN |
|
Perficient Inc
NASDAQ:PRFT
|
US |
|
D
|
Digital Workforce Services Oyj
OMXH:DWF
|
FI |
Biome Australia Ltd
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.
Record Revenue: Biome Australia delivered record sales revenue of $12.4 million for H1 FY26, growing 40% year-over-year.
Profitability Milestone: Net profit after tax reached $1.18 million, with adjusted EBITDA hitting $1.47 million—marking the eighth consecutive quarter of positive EBITDA.
Strong Gross Margins: Gross margin held above 61%, reflecting premium positioning and effective pricing.
Market Leadership: Activated Probiotics is now the #2 probiotic brand by revenue in Australian community pharmacy and is on track to take the #1 spot soon.
Clinical Differentiation: Biome emphasizes its competitive edge through more than 30 clinical trials, including world-first studies on new strains like BMB18.
Distribution Expansion: The company has surpassed 7,000 Australian distribution points, aiming for over 7,500 by year-end.
International Growth: Strong early results in Canada and launches in Ireland, the UK, and New Zealand point to accelerating global expansion.
Lean Marketing Spend: Only 7.5% of sales revenue was spent on marketing in H1, with most commercial costs tied to staffing and distribution.
